All times shown in GMT - please see the Full Event Guide for CET

8:00 am Virtual Coffee Networking Rooms

8:45 am Chair’s Opening Remarks

9:00 am Providing an Overview of the European CAR-T Landscape

9:30 am Automated manufacturing technologies to accelerate the development of tomorrow’s therapies

10:00 am Developing Parallel CAR-T for Increased Efficacy

  • John Maher Immunology Consultant, King’s College London / CSO , Leucid Bio

10:30 am Refreshment Break & Networking

Research & Development

Translation & Clinical

Manufacturing & Commercialisation

Progress in Next-Generation Target Identification

Enhancing CAR-T for Haematological Conditions

Optimising Clinical Development
& Affordability in Europe

11.30 One Stone, Three Birds: Tri-Functional CAR-T for Solid Tumours

To see full session details, download the full event guide

Bin Gao, CSO & CEO, Timmune Biotech

11:30 BCMA as an Ideal Target for Treating
Myeloma and Global Competition in BCMA Targeting Immunotherapies

To see full session details, download the full event guide

Frank Fan, Co-Founder & CSO, Legend Biotech

11.30 Developing European Standards for
Clinical Delivery of Cell Immunotherapies

To see full session details, download the full event guide

Nina Worel, Medical Director of Tissue & Cell Collection & Processing Facility, Medical University Vienna

12:00 Systemised Cell Biology Approaches
Enabling TCR-based Cellular Therapies

To see full session details, download the full event guide

Reagan Jarvis, CEO, Anocca AB

 

12:00 Examining Real-World Results in CD19 CAR-T in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

To see full session details, download the full event guide

Catherine Thieblemont, Head of Haemato-Oncology Department, Hôpital Saint-Louis

 

12:00 New platform which standardises the creation of clonal master cell banks for gene-edited iPSCs used in clinical manufacturing of allogeneic immunotherapies

To see full session details, download the full event guide

Ian Taylor, Chief Business Officer, Solentim

 

12:30 Developing a Highly Efficient Platform for TCR Identification in Solid Tumour Indications

To see full session details, download the full event guide

Felix Lorenz, Head, Captain T Cell

 

12:30

12:30 Developing Closed-System Clinical Scale Production Method for Reduced Cost of Manufacture

To see full session details, download the full event guide

Volker Huppert, CDO, Glycostem

1:00 Selection of True TCR Targets Using Humanised TCR Mice

To see full session details, download the full event guide

Elisa Kieback, CEO, T-Knife

 

1:00 Panel Discussion: Addressing Unintentional Biases in Clinical Trials to Reveal True Therapeutic Value in the Real World

To see full session details, download the full event guide

Noah Berkowitz, SVP, Development Unit Head, Hematology, Bristol Myers Squibb

Catherine Thieblemont, Head of Haemato-Oncology Department, Hôpital Saint-Louis

 

1:00 Setting the Bar with Two Commercial CAR-T Products, and Next Steps for the Industry to Advance the Field

To see full session details, download the full event guide

Krishnan Viswanadhan, SVP, Global Cell Therapy Franchise Lead, Bristol Myers Squibb

1:30 pm Lunchtime Refreshments

Research & Development

Translation & Clinical

Manufacturing & Commercialisation

Innovations & Next-Generation CAR Technologies

Combination & Multi-Targeting Approaches for Enhanced Solid Tumour Efficacy

Pricing & Reimbursement Strategy in a Single Payer System

14:00 Breakthroughs in HIV Treatment with Dual CAR-T Using Lessons Learned from CAR-T for Oncology

To see full session details, download the full event guide

James Riley, Professor of Microbiology, University of Pennsylvania

 

14:00 Contrasting Checkpoint Inhibitors in Combination with CAR-T and as Engineered CARs for Optimal Solid Tumour Impact

To see full session details, download the full event guide

Blake Aftab, VP, Preclinical & Translational Science, Atara Biotherapeutics

 

14:00 Case Study: Challenges and Potential Solutions to Value Assessment and Reimbursement of CAR-T Therapies in Europe

To see full session details, download the full event guide

Trevor Bacon, Compound Market Access Leader (EMEA), Cell & Gene Therapies, Janssen

14:30 Introducing DAR-T Technology for Improved Specificity and Safety, “Off-the-Shelf”

To see full session details, download the full event guide

Wenzhong Guo, CTO, Cell Therapy, Sorrento Therapeutics Inc

 

14.30 Heating Things Up: Combination Strategies to Access Cold Tumours

To see full session details, download the full event guide

Laurence Cooper, CEO, Ziopharm Oncology

 

14:30 Challenges faced by cell and gene therapy (CGT) treatment delivery centres and implications for
pharma-provider engagement

To see full session details, download the full event guide

Maya Khurana, Director, Huron

Filiz Yucebay, Manager, Huron

15:00 Next-Generation Gene Editing Technology for Allogeneic Immune Cell Therapeutics

To see full session details, download the full event guide

Steven Kanner, Chief Scientific Officer, Caribou Biosciences

 

15:00 Discussing Clinical Management and Outcomes in Delivering MultiTAA Therapy in Challenging Pancreatic Solid tumour Indications

To see full session details, download the full event guide

Mythili Koneru, CMO, Marker Therapeutics

 

15:00 Bridging the Gap Between “Evidence” and “Value” for Cell and Gene Therapies

To see full session details, download the full event guide

Jie Zhang, Head of Global Access & Value, Cell & Gene Therapy, Novartis

3:30 pm Afternoon Refreshments

4:00 pm Exploring the use of Engineered Natural Killer Cells for Allogeneic Therapy

4:30 pm Describing Innovative Payment Models for Reimbursement of High-Cost, Single-Treatment Therapies to Improve Patient Access

  • Alla Uhrlandt EMEA Strategic Pricing Manager Cell & Gene Therapies, Janssen

5:00 pm Discussing the Implications of Brexit forCell and Gene Therapies

5:30 pm Chair’s Closing Remarks

5:45 pm Close of Summit